Revenue recognition from Collaboration and License Agreements - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended		6 Months Ended
	Mar. 31, 2024	May 31, 2020	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Feb. 29, 2024	Dec. 31, 2023
Disaggregation of Revenue [Line Items]
Revenue from collaboration agreements			$ 1,073	$ 30,249	$ 53,477	$ 35,927
Roche
Disaggregation of Revenue [Line Items]
Revenue from collaboration agreements			1,073	4,825	50,888	10,137
Roche | Completion of Continuing Trials [Member]
Disaggregation of Revenue [Line Items]
Deferred revenue			0		0			$ 9,463
Roche | Collaboration and License Agreement
Disaggregation of Revenue [Line Items]
Collaboration payable	$ 500
Milestones payments received							$ 40,000
Deferred revenue recognized			1,100	4,800	50,900	10,100
Roche | Collaboration and License Agreement | Third Additional Clinical Development Plan
Disaggregation of Revenue [Line Items]
Collaboration revenue received	4,000
Collaboration revenue receivable earned								$ 2,100
Bristol-Myers Squibb Company
Disaggregation of Revenue [Line Items]
Revenue from collaboration agreements			0	14,951	2,589	15,317
Bristol-Myers Squibb Company | Collaboration and License Agreement
Disaggregation of Revenue [Line Items]
Collaboration term expiration date		Nov. 30, 2023
Bristol-Myers Squibb Company | Collaboration and License Agreement | Undruggable targets
Disaggregation of Revenue [Line Items]
Deferred revenue recognized	2,600
Option fee payment	$ 100
Bristol-Myers Squibb Company | Collaboration and License Agreement | Maximum
Disaggregation of Revenue [Line Items]
Milestone payments entitled to be received		$ 301,000
Bristol-Myers Squibb Company | Collaboration and License Agreement | Maximum | Research, Development and Regulatory Milestones
Disaggregation of Revenue [Line Items]
Milestone payments entitled to be received		176,000
Bristol-Myers Squibb Company | Collaboration and License Agreement | Maximum | Commercial Milestones
Disaggregation of Revenue [Line Items]
Milestone payments entitled to be received		$ 125,000
Ono Collaboration Agreement
Disaggregation of Revenue [Line Items]
Revenue from collaboration agreements			$ 0	$ 10,473	$ 0	$ 10,473